Companies willing to pay high prices for novel treatments are hampering GlaxoSmithKline's efforts to boost its pipeline through drug acquisitions, said Moncef Slaoui, GSK's head of research. Slaoui said the strategy by "desperate" rival drugmakers will not be used by GSK, which plans to announce next month its expansion into medicines for rare diseases.

Full Story:

Related Summaries